Issues

SC Conference on Biomedical R&D for Public Health in India, 13-14 August 2018

Title:                Conference on Biomedical R&D for Public Health in India

Date:                13-14 August 2018

Venue:              Vivanta Ambassador Hotel, New Delhi, India 

Organizers:     The South Centre, the Council for Scientific and Industrial Research, the Pharmaceuticals Export Promotion Council of India (PHARMEXCIL)

(more…)

Tax Cooperation Policy Brief 3, August 2018

Interaction of Transfer Pricing & Profit Attribution: Conceptual and Policy Issues for Developing Countries

Till 2010, model tax conventions treated profit attribution to permanent  establishments  and transfer  pricing under  different  articles,  and  profit  attribution under Article  7  allowed sales to be taken into account both in the direct accounting method as well as the indirect apportionment  method.  However,  the  revised  Article  7  in  the  2010 update of the OECD Convention approximated profit  attribution  with  transfer  pricing  and  omitted  the option  of  apportionment,  thereby  undermining  sales  and contributions   made   by   market   jurisdiction   to   business profits. When a tax treaty retains Article 7 based on the UN Convention  or  the  earlier  OECD  Convention,  Contracting States  can  take  sales  into  account  and  also  opt  for  apportionment.  Developing  countries  need  to  fully  understand these implications of  Article  7 in their tax treaties, and opt for informed choices for transfer pricing and profit attribution  to  permanent  establishments,  including  apportionment that takes sales into account.

(more…)

SC Conference on TRIPS-CBD, 7-8 June 2018

Title:                 International Conference on TRIPS-CBD Linkage: Issues and Way Forward

Date:                7-8 June 2018

Venue:              Room IX, Palais des Nations, Geneva

Organizers:     The South Centre, Centre for WTO Studies and the Indian Institute of Foreign Trade, co-sponsored by the Permanent Missions of Brazil, India, Indonesia and South Africa to the WTO

(more…)

SC Side Event to the WHA71, 25 May 2018

Title:                 Side Event to the 71st World Health Assembly, on Access to Medicines: Overcoming Obstacles created by monopolies – Essential to UHC and the 2030 Agenda

Date:                 25 May 2018

Venue:              Room VIII, Palais des Nations, Geneva

Organizers:     Missions of Brazil, India, Morocco, Senegal, and Thailand, with the support of the South Centre

(more…)

SC WHO-NGO Dialogue on AMR, 9 May 2018

Title:                 Fourth Annual WHO-NGO Dialogue in Geneva

Date:                 9 May 2018

Venue:              The South Centre, Geneva

Organizers:     The South Centre, Third World Network and ReAct

(more…)

SC Consultations with the IACG Subgroup 4, 8 May 2018

Title:                 Consultations with the United Nations Interagency Coordination Group on Antimicrobial Resistance (IACG) Subgroup 4 on Innovation and Access

Date:                 8 May 2018

Venue:              The South Centre, Geneva

Organizers:     The South Centre, Third World Network and ReAct

(more…)

SC Workshop on AMR for CSOs, 7-9 May 2018

Title:                   Charting a Future Free from the Fear of Untreatable Infections

Date:                   7-9 May 2018

Venue:                The South Centre, Geneva

Organizers:        The South Centre, Third World Network and ReAct

(more…)

Policy Brief 49, July 2018

Major Outcomes of the 71st Session of the World Health Assembly of WHO

The 71st session of the World Health Assembly (WHA) of the World Health Organization (WHO) took place from 21 to 26 May 2018 in Geneva, Switzerland. The Assembly adopted several decisions and resolutions including the adoption of the General Programme of Work (GPW) of WHO for the period 2019-2023, as well as decisions on addressing access to medicines and vaccines and their global shortage, and the recommendations of an overall programme review of the WHO Global Strategy and Plan of Action on Public Health, Innovation and Intellectual Property (GSPA-PHI).   (more…)

Documento de Investigación 85, Mayo 2018

Acceso a medicamentos: experiencias con licencias obligatorias y uso gubernamental – el caso de la Hepatitis C

El acceso a medicamentos está fuertemente condicionado por su precio y por los mecanismos de financiamiento que pueden aplicarse en cada país. […] Un factor determinante en la fijación del precio de los medicamentos es el grado de competencia existente en una particular clase terapéutica, la que a su vez es influenciada por la existencia o no de derechos de propiedad intelectual, como patentes de invención.

(more…)


0

Your Cart